Cargando…

Comment on Albogami et al. Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344–1352

Detalles Bibliográficos
Autores principales:	Foer, Dinah, Cahill, Katherine N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2021
Materias:	e-Letters: Comments and Responses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385467/ https://www.ncbi.nlm.nih.gov/pubmed/34285099 http://dx.doi.org/10.2337/dc21-0904

Ejemplares similares

Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901–907
por: Østergaard, Helena Bleken, et al.
Publicado: (2021)

Comment on Lachin et al. The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes. Diabetes Care 2021;44:2225–2230
por: Quinn, Lauren M., et al.
Publicado: (2022)

Response to Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901–907
por: Vistisen, Dorte, et al.
Publicado: (2021)

Comment on Dawed et al. Genome-Wide Meta-Analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673–2682
por: Wang, Ke, et al.
Publicado: (2022)

Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673–2682
por: Dawed, Adem Y., et al.
Publicado: (2022)

Comment on Lee et al. Multicenter, Head-to-Head, Real-World Validation Study of Seven Automated Artificial Intelligence Diabetic Retinopathy Screening Systems. Diabetes Care 2021;44:1168–1175
por: Soliz, Peter
Publicado: (2021)

Response to Comment on Gregory et al. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic’s Impact in Type 1 and Type 2 Diabetes. Diabetes Care 2021;44:526–532
por: Gregory, Justin M., et al.
Publicado: (2021)

Response to Comment on Lee et al. Multicenter, Head-to-Head, Real-World Validation Study of Seven Automated Artificial Intelligence Diabetic Retinopathy Screening Systems. Diabetes Care 2021;44:1168–1175
por: Lee, Aaron Y., et al.
Publicado: (2021)

Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2016;39:264–270
por: Rickels, Michael R., et al.
Publicado: (2016)

Reply to Watchorn et al.: Asthma Exacerbations in Individuals on Glucagon-like Peptide-1 Receptor Agonists for Type 2 Diabetes
por: Foer, Dinah, et al.
Publicado: (2021)

Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)
por: Lin, Tzu-Yi, et al.
Publicado: (2023)

Comment on Menke et al. Metals in Urine and Diabetes in U.S. Adults. Diabetes 2016;65:164–171
por: Wong, Winifred P., et al.
Publicado: (2016)

Response to Comment on Malik. Which Test for Diagnosing Early Human Diabetic Neuropathy? Diabetes 2014;63:2206–2208
por: Petropoulos, Ioannis N., et al.
Publicado: (2015)

Comment on Löndahl. Number Eight in the Service of Diabetic Foot Ulcer Healing. Diabetes Care 2020;43:515–517
por: Frykberg, Robert G.
Publicado: (2020)

Comment on Young-Hyman et al. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140
por: Mezuk, Briana, et al.
Publicado: (2017)

Response to Comment on Jaiswal et al. Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study. Diabetes Care 2017;40:1226–1232
por: Jaiswal, Mamta, et al.
Publicado: (2018)

Response to Comment on Young-Hyman et al. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140
por: Young-Hyman, Deborah, et al.
Publicado: (2018)

Response to Comments on Young-Hyman et al. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140
por: Young-Hyman, Deborah, et al.
Publicado: (2017)

Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes—2016. Diabetes Care 2016;39(Suppl. 1):S52–S59
por: Herman, William H., et al.
Publicado: (2016)

Comment on Mizokami-Stout et al. The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange. Diabetes Care 2020;43:806–812
por: Kostev, Karel
Publicado: (2020)

Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care 2017;40:777–783
por: Lachin, John M., et al.
Publicado: (2017)

Response to Comment on Mizokami-Stout et al. The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange. Diabetes Care 2020;43:806–812
por: Mizokami-Stout, Kara R., et al.
Publicado: (2020)

Comment on Moore et al. Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. Diabetes Care 2013;36:2981–2987
por: Goodarzi, Mark O.
Publicado: (2014)

Response to Comment on Laiteerapong et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care 2019;42:416–426
por: Laiteerapong, Neda, et al.
Publicado: (2019)

Response to Comment on Cefalu et al. The Alarming and Rising Costs of Diabetes and Prediabetes: A Call for Action! Diabetes Care 2014;37:3137–3138
por: Cefalu, William T., et al.
Publicado: (2015)

Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014;37:1499–1508
por: Home, Philip, et al.
Publicado: (2014)

Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684–1692
por: Inzucchi, Silvio E., et al.
Publicado: (2017)

Response to Comment on Sims et al. Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. Diabetes Care 2019;42:258–264
por: Sims, Emily K., et al.
Publicado: (2019)

Response to Comment on Vassy et al. Polygenic Type 2 Diabetes Prediction at the Limit of Common Variant Detection. Diabetes 2014;63:2172–2182
por: Vassy, Jason L., et al.
Publicado: (2014)

Response to Comment on Lontchi-Yimagou et al. An Atypical Form of Diabetes Among Individuals With Low BMI. Diabetes Care 2022;45:1428–1437
por: Lontchi-Yimagou, Eric, et al.
Publicado: (2022)

Comment on Duarte et al. Systematic Review and Network Meta-analysis of Neurostimulation for Painful Diabetic Neuropathy. Diabetes Care 2022;45:2466–2475
por: Sharan, Ashwini D., et al.
Publicado: (2023)

Comment on Skudder-Hill et al. Fat Distribution Within the Pancreas According to Diabetes Status and Insulin Traits. Diabetes 2022;71:1182–1192
por: Yang, Jie, et al.
Publicado: (2022)

Comment on Koivusalo et al. Gestational Diabetes Mellitus Can Be Prevented by Lifestyle Intervention: The Finnish Gestational Diabetes Prevention Study (RADIEL): A Randomized Controlled Trial. Diabetes Care 2016;39:24–30
por: Bao, Wei
Publicado: (2016)

Comment on Davis et al. Development and Validation of a Simple Hip Fracture Risk Prediction Tool for Type 2 Diabetes: The Fremantle Diabetes Study Phase I. Diabetes Care 2018;42:102–109
por: Bůžková, Petra, et al.
Publicado: (2019)

Response to Comment on Misra et al. Homozygous Hypomorphic HNF1A Alleles Are a Novel Cause of Young-Onset Diabetes and Result in Sulfonylurea-Sensitive Diabetes. Diabetes Care 2020;43:909–912
por: Misra, Shivani, et al.
Publicado: (2020)

Comment on Bonnet et al. Association Between Handedness and Type 2 Diabetes: The E3N Study. Diabetes Care 2015;38:e199
por: Selvin, Elizabeth
Publicado: (2016)

Comment on Vimalananda et al. Depressive Symptoms, Antidepressant Use, and the Incidence of Diabetes in the Black Women’s Health Study. Diabetes Care 2014;37:2211–2217
por: Kivimäki, Mika, et al.
Publicado: (2015)

Response to Comment on Hedderson et al. Prepregnancy SHBG Concentrations and Risk for Subsequently Developing Gestational Diabetes Mellitus. Diabetes Care 2014;37:1296–1303
por: Hedderson, Monique M., et al.
Publicado: (2014)

Response to Comment on Lacy et al. Long-term Glycemic Control and Dementia Risk in Type 1 Diabetes. Diabetes Care 2018;41:2339–2345
por: Lacy, Mary E., et al.
Publicado: (2019)

Comment on Piccinini and Bergman. The Measurement of Insulin Clearance. Diabetes Care 2020;43:2296–2302
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nbjqgduqu90krmdfv1ntccugmr